Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors

Blood

Volumn 101, Issue 3, 2003, Pages 1080-1086

  Tehranchi, Ramin ^a   Fadeel, Bengt ^a   Forsblom, Ann Mari ^a   Christensson, Birger ^a   Samuelsson, Jan ^a   Zhivotovsky, Boris ^a   Hellstrom Lindberg, Eva ^a,b  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CASPASE 9; CD34 ANTIGEN; CYTOCHROME C; ERYTHROPOIETIN; FAS ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW BIOPSY; BONE MARROW DISEASE; CELL CULTURE; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME RELEASE; ERYTHROBLAST; ERYTHROID PRECURSOR CELL; HEMATOPOIETIC STEM CELL; HUMAN; MITOCHONDRION; MOLECULAR MECHANICS; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REFRACTORY ANEMIA; SIDEROBLASTIC ANEMIA; SIGNAL TRANSDUCTION;

EID: 0037307728     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-06-1774     Document Type: Article

References (44)

1. Aul C, Bowen DT, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica. 1998;83:71-86.
2. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
3. Raza A, Gezer S, Mundle S, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood. 1995;86:268-276.
4. Hellstrom-Lindberg E, Kanter-Lewensohn L, Ost A. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk Res. 1997;21:415-425.
5. Parker JE, Fishlock KL, Mijovic A, Czepulkowski B, Pagliuca A, Mufti GJ. 'Low-risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro-versus antiapoptotic bcl-2-related proteins. Br J Haematol. 1998;103:1075-1082.
6. Gersuk GM, Lee JW, Beckham CA, Anderson J, Deeg HJ. Fas (CD95) receptor and Fas-ligand expression in bone marrow cells from patients with myelodysplastic syndrome. Blood. 1996;88:1122-1123.
7. Bouscary D, De Vos J, Guesnu M, et al. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia. 1997;11:839-845.
8. Lepelley P, Grardel N, Erny O, et al. Fas/APO-1 (CD95) expression in myelodysplastic syndromes. Leuk Lymphoma. 1998;30:307-312.
9. Gersuk GM, Beckham C, Loken MR, et al. A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol. 1998;103:176-188.
10. Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281:1309-1312.
11. Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407:770-776.
12. Bessho F, Ohnishi H, Tabuchi K, Kobayashi M, Hayashi Y. Significance of electron-dense deposits in the mitochondrial matrix of erythroid precursors in aplastic anaemia and myelodysplastic syndrome. Br J Haematol. 1999;105:149-154.
13. Gattermann N, Retzlaff S, Wang YL, et al. Heteroplasmic point mutations of mitochondrial DNA affecting subunit I of cytochrome c oxidase in two patients with acquired idiopathic sideroblastic anemia. Blood. 1997;90:4961-4972.
14. Reddy PL, Shetty VT, Dutt D, et al. Increased incidence of mitochondrial cytochrome c-oxidase gene mutations in patients with myelodysplastic syndromes. Br J Haematol. 2002;116:564-575.
15. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood. 1998;92:68-75.
16. Remacha AF, Arrizabalaga B, Villegas A, et al. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group. Haematologica. 1999;84:1058-1064.
17. Mantovani L, Lentini G, Hentschel B, et al. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoletin. Br J Haematol. 2000;109:367-375.
18. Schmidt-Mende J, Tehranchi R, Forsblom AM, et al. Granulocyte colony-stimulating factor inhibits Fas-triggered apoptosis in bone marrow cells isolated from patients with refractory anemia with ringed sideroblasts. Leukemia. 2001;15:742-751,
19. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
20. Hellstrom-Lindberg E, Schmidt-Mende J, Forsblom AM, Christensson B, Fadeel B, Zhivotovsky B. Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases. Br J Haematol. 2001;112:714-726.
21. Freyssinier JM, Lecoq-Lafon C, Amsellem S, et al. Purification, amplification and characterization of a population of human erythroid progenitors. Br J Haematol. 1999;106:912-922.
22. Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 1995;376:37-43.
23. Joseph B, Ekedahl J, Lewensohn R, Marchetti P, Formstecher P, Zhivotovsky B. Defective caspase-3 relocalization in non-small cell lung carcinoma. Oncogene. 2001;20:2877-2888.
24. Fadeel B, Orrenius S, Zhivotovsky B. The most unkindest cut of all: on the multiple roles of mammalian caspases. Leukemia. 2000;14:1514-1525.
25. Hellstrom-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietln for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol. 1997;99:344-351.
26. Claessens Y-E, Bouscary D, Dupont J-M, et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood. 2002;99:1594-1601
27. Maciejewski JP, Selleri C, Sato T, Anderson S, Young NS. Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. Br J Haematol. 1995;91:245-252.
28. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 1998;94:491-501.
29. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 1998;94:481-490.
30. Yin XM, Wang K, Gross A, Zhao Y, Zinkel S, Klocke B, Roth KA, Korsmeyer SJ. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature. 1999;400:886-891.
31. Scaffidl C, Fulda S, Srinivasan A, et al. Two CD95 (APO-1/Fas) signaling pathways. Embo J. 1998;17:1675-1687.
32. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-199.
33. Juneja SK, Imbert M, Sigaux F, Jouault H, Sultan C. Prevalence and distribution of ringed sideroblasts in primary myelodysplastic syndromes. J Clin Pathol. 1983;36:566-569.
34. May A, de Souza P, Barnes K, Kaaba S, Jacobs A. Erythroblast iron metabolism in sideroblastic marrows. Br J Haematol. 1982;52:611-621.
35. Williams GT, Smith CA, Spooncer E, Dexter TM, Taylor DR. Haemopoletic colony stimulating factors promote cell survival by suppressing apoptosis. Nature. 1990;343:76-79.
36. Colotta F, Re F, Polentarutti N, Sozzani S, Mantovani A. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood. 1992;80:2012-2020.
37. Brach MA, deVos S, Gruss HJ, Herrmann F. Prolongation of survival of human polymorphonuclear neutrophils by granulocyte-macrophage colony-stimulating factor is caused by inhibition of programmed cell death. Blood. 1992;80:2920-2924.
38. Dibbert B, Weber M, Nikolaizik WH, et al. Cytokine-mediated Bax deficiency and consequent delayed neutrophil apoptosis: a general mechanism to accumulate effector cells in inflammation. Proc Natl Acad Sci U S A. 1999;96:13330-13335.
39. Malanski NA, Mul FP, van Buul JD, Roos D, Kuijpers TW. Granulocyte colony-stimulating factor inhibits the mitochondria-dependent activation of caspase-3 in neutrophils. Blood. 2002;99:672-679.
40. Dewson G, Cohen GM, Wardlaw AJ. Interleukin-5 inhibits translocation of Bax to the mitochondria, cytochrome c release, and activation of caspases in human eoslnophils. Blood. 2001;98:2239-2247.
41. Villunger A, O'Reilly LA, Holler N, Adams J, Strasser A. Fas ligand, Bcl-2, granulocyte colony-stimulating factor, and p38 mitogen-activated protein kinase: regulators of distinct cell death and survival pathways in granulocytes. J Exp Med. 2000;192:647-658.
42. Mundle SD, Ali A, Cartlidge JD, et al. Evidence for involvement of tumor necrosis factor-alpha in apoptotic death of bone marrow cells in myelodysplastic syndromes. Am J Hematol. 1999;60:36-47.
43. Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopolesis. Blood. 2001;98:3058-3065.
44. Plasilova M, Zivny J, Jelinek J, et al. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasla progenitors. Leukemia. 2002;16:67-73.